TRANSIL PPB Binding Kit

Sovicell Verified independent store

→

Rapid Determination of Human Plasma Protein Binding Using Immobilized Albumin and AGP The TRANSIL PPB Binding Kit enables rapid determination of human plasma protein binding (fract ion unbound, fu) by measuring compound interactions with the two principal plasma binding proteins, human serum albumin (HSA) and α1-acid glycoprotein (AGP). The assay uses a defined mixture of albumin- and AGP-coated beads prepared to approximate their typical molar ratio in human plasma. Why Plasma Protein Binding Matters Most drug molecules are reversibly bound to proteins in plasma. Only the unbound fraction (fu) can cross biological membranes, interact with pharmacological targets, or undergo metabolic elimination. Plasma protein binding therefore strongly influences drug exposure, pharmacokinetics, and pharmacological activity. While human serum albumin is the most abundant plasma protein, α1-acid glycoprotein (AGP) can dominate the binding of basic and lipophilic drugs. Accurate estimation of plasma protein binding therefore requires consideration of both proteins. Because plasma protein binding can substantially reduce the circulating free drug concentration, accurate characterization of plasma protein binding is an important component of ADME profiling and lead optimization. Plasma protein binding influences many key parameters in ADME and DMPK, including: prediction of the unbound drug fraction in plasma interpretation of potency in serum-containing assays estimation of clearance, half-life, and volume of distribution assessment of potential drug–drug interactions Limitations of Conventional Plasma Protein Binding Assays Conventional approaches for measuring plasma protein binding, such as equilibrium dialysis, ultrafiltration, and ultracentrifugation, directly determine the free fraction of a compound in plasma. While widely used, these methods can be time-consuming and experimentally demanding, often requiring long equilibration times and careful control of experimental conditions. In addition, adsorption to membranes or plastic surfaces, compound instability, and analytical sensitivity limitations can complicate the accurate measurement of highly bound compounds. These challenges make it difficult to apply traditional methods efficiently in high-throughput drug discovery workflows. The TRANSIL Approach: Mimicking Plasma Protein Binding In Vitro The TRANSIL PPB Binding Kit provides rapid estimation of human plasma protein binding by measuring compound interactions with the two principal plasma binding proteins: human serum albumin (HSA) and α1-acid glycoprotein (AGP). These proteins account for the majority of reversible drug binding in plasma, with albumin typically dominating the binding of neutral and acidic compounds, while AGP often contributes significantly to the binding of basic drugs. To mimic the binding environment in plasma, the assay uses a defined mixture of albumin-coated and AGP-coated beads prepared to approximate their typical molar ratio in human plasma (approximately 24:1). Test compounds are incubated with increasing concentrations of this protein mixture under well-defined experimental conditions. Binding of the compound to the immobilized proteins reduces the free drug concentration in solution, which is quantified analytically. From the resulting binding curve, an apparent binding constant is calculated that describes the interaction of the compound with the combined protein system. This parameter represents an operational binding constant rather than a mechanistic affinity for a specific protein. It is used internally to calculate the fraction of compound bound to plasma proteins and to support quality control of the assay. By directly measuring compound interaction with the two dominant plasma binding proteins in a defined system, the TRANSIL PPB Binding Kit enables rapid and robust estimation of plasma protein binding (fu) without the need for dialysis membranes or long equilibration times. Compared with conventional equilibrium dialysis experiments, the assay provides significantly faster turnaround and improved robustness. This approach captures the dominant plasma protein binding interactions while providing a faster and more economical alternative to measuring albumin and AGP binding separately. How the Assay Works The assay estimates plasma protein binding through the following experimental workflow: Test compound is added at constant concentration to 8 wells The compound is incubated with increasing concentrations of a defined mixture of albumin- and AGP-coated beads Beads are separated, leaving only free drug in solution Free drug concentration is quantified (e.g., by LC–MS/MS) Plasma protein binding is calculated from the apparent binding constant describing interaction with the combined HSA–AGP system Features and Benefits Membrane-free binding measurement Immobilization of albumin on beads eliminates the need for dialysis membranes, accelerating equilibration between compound and protein while avoiding artifacts caused by membrane adsorption or slow diffusion through dialysis membranes. Rapid equilibrium measurements Immobilized albumin on high-surface-area beads enables equilibrium binding measurements within 12 minutes or less rather than the hours required for dialysis-based methods. Direct estimation of plasma protein binding The assay measures compound binding to a mixture of albumin and AGP that approximates their physiological abundance, enabling rapid estimation of the fraction unbound in human plasma. Robust performance for challenging compounds Affinity is derived from the relationship between binding and protein concentration, making the method largely insensitive to compound loss caused by nonspecific adsorption or limited recovery. Stable and controlled pH conditions The assay is performed in a well-defined buffered environment, preventing errors in free fraction (fu) estimation caused by pH shifts that can occur in dialysis experiments. Well-defined experimental conditions Binding is measured against purified albumin and AGP at controlled concentrations, reducing variability associated with plasma composition and improving reproducibility. High-throughput assay format The 96-well format allows analysis of up to 12 compounds per plate, supporting efficient profiling during lead optimization. Compatibility with standard analytical methods Free compound concentration can be quantified using LC–MS/MS, HPLC, or other commonly used analytical techniques, allowing integration into existing workflows. Integrated internal quality control The TRANSIL Quality Index (TQI) evaluates data reliability using multiple statistical and experimental metrics, providing an objective assessment of assay performance within each experiment. Positioning vs Other TRANSIL Kits Compared with the individual HSA and AGP binding assays, the TRANSIL PPB Binding Kit provides a faster and more economical method for estimating plasma protein binding, while the individual assays offer deeper mechanistic insight into protein-specific binding interactions. Plasma Protein Binding in Preclinical Species Customized TRANSIL PPB Kits for preclinical species such as rat, mouse, or monkey are available upon request. These kits use species-specific mixtures of albumin- and AGP-coated beads that reproduce the typical plasma concentrations and ratios of these proteins in the respective species, enabling estimation of plasma protein binding under physiologically relevant conditions. Validation Against Literature and Equilibrium Dialysis The performance of the TRANSIL PPB Binding assay was evaluated using a validation set of 26 structurally diverse drugs with plasma protein binding values reported in the literature or determined by equilibrium dialysis. The compounds covered a broad range of binding properties and physicochemical characteristics, including both acidic and basic drugs known to interact preferentially with human serum albumin (HSA) or α1-acid glycoprotein (AGP). In the validation experiments, binding to albumin-coated and AGP-coated beads was measured individually and in combination. The combined protein system reflects the typical molar ratio of albumin and AGP found in human plasma and therefore captures the dominant plasma protein binding interactions for most drug molecules. Plasma protein binding values estimated using the TRANSIL PPB approach showed strong agreement with literature and equilibrium dialysis measurements, demonstrating that compound interaction with the combined albumin–AGP system provides a reliable approximation of plasma protein binding. These results confirm that measuring binding to the two principal plasma proteins in a defined in-vitro system enables rapid and robust estimation of the fraction unbound (fu) in human plasma, while avoiding the long equilibration times and experimental variability associated with dialysis-based methods. Figure 1: Comparison of plasma protein binding measurements obtained with the TRANSIL assay kits and dialysis as well as comparison with literature data (Goodman and Gilman 1996: The Pharmacological Basis of Therapeutics). What are the main quality control measures applied in TRANSIL assays? The TRANSIL Quality Index (TQI) is based on independent measures derived from the data analysis. Overall fit of the data to the standard protein binding model Recovery: does the model derived compound concentration equal the true concentration? Data consistency: does membrane binding increase proportionally with the increasing TRANSIL bead content in each well? Data consistency: are the estimated reference concentrations in alignment with the compound concentration used? Missing data and outliers. How long does it take to run the assay? One assay plate can be used for 12 compounds. Thus, you’ll need to pipette 15 µl of test item to each of 8 wells and repeat this for all 12 compounds. This takes less than 10 minutes even with manual pipetting. After compound addition, the plate is ready for incubation. You can do this with an electronic 8 or 12 channel pipette by aspirating and dispensing a volume of 120 µl for 15 times. That takes just over a minute for each column or row. In total, that makes 8 to 15 minutes depending on your pipette. When using a pipetting robot with a 96 well head this time decreases to 2 minutes. After incubation, the plate needs to be spun in a plate centrifuge for 10 minutes. The supernatants are then ready for quantification by LC/MS/MS, UV, fluorescence or any other method of your choice. Thus, the total time the start and end of the experiment varies between 7 and 25 minutes depending upon your equipment. How many compounds can be analyzed with one plate? One assay plate can be used for 12 compounds. A special feature of the 96 well plates used for these kits is that each of the 12 columns can be separated from the plate. Thus, it is possible to use the plate for one compound at a time. Are TRANSIL assay kits supplied in low-binding plates? The TRANSIL assay kits utilize Micronic 96 well plates with ultra-low-binding tubes. Standard polypropylene tubes have 41x higher non-specific binding and low-binding tubes from other vendors have 2.6x higher non-specific binding. Show more